FindTrial
Sign In

Retrospective study on the predictive value of free status achieved during mid-term liver cancer treatment for the prognosis of liver cancer patient

Retrospective study on the predictive value of cancer free status during dynamic treatment for intermediate stage hepatocellular carcinoma

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2400084930
Enrollment
Unknown
Registered
2024-05-28
Start date
2024-05-31
Completion date
Unknown
Last updated
2024-06-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hepatocellular carcinoma, HCC

Interventions

INTERVENTIONAL:Exposure: Cancer Free Status

Sponsors

Sun Yat-sen University Cancer Center
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 85 Years

Inclusion criteria

Inclusion criteria: a) Clinical or pathological diagnosed HCC; b) BCLC Stage B HCC: 2-3 lesions with a maximum diameter greater than 3cm; More than or equal to 4 intrahepatic lesions. c) Received interventional therapy based comprehensive treatment; d) ECOG PS score 0-1.

Exclusion criteria

Exclusion criteria: a) History of other malignant tumors within 5 years (excluding early stage basal cell carcinoma, cervical carcinoma in situ and Papillary thyroid carcinoma) b) ECOG PS score = 2; c) Child Pugh score = 7; Decompensation of liver function, such as the appearance of large amounts of ascites, gastric fundus and esophageal veins varicocephaly together with upper gastrointestinal bleeding within 1 year, hepatic encephalopathy and bilirubin encephalopathy.

Design outcomes

Primary

MeasureTime frame
Overall survival;—

Countries

China

Contacts

Public ContactWeijun Fan

Sun Yat-sen University Cancer Center

fanwj@sysucc.org.cn+86 138 2615 4530

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026